MENU
JDOC
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

JDOC stock forecast, quote, news & analysis

The investment seeks to provide long-term capital appreciation... Show more

Category: #Health
JDOC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for JDOC with price predictions
Oct 01, 2026

JDOC in downward trend: price dove below 50-day moving average on September 08, 2026

JDOC moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend. In 15 of 19 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JDOC as a result. In 34 of 48 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.

The Moving Average Convergence Divergence Histogram (MACD) for JDOC turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 27 similar instances when the indicator turned negative. In 20 of the 27 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

The 10-day moving average for JDOC crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 6 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JDOC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for JDOC's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +0.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where JDOC advanced for three days, in 89 of 118 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

JDOC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 121 of 152 cases where JDOC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Abbott Laboratories (NYSE:ABT), Bristol-Myers Squibb Co (NYSE:BMY), CVS HEALTH Corp (NYSE:CVS), Regeneron Pharmaceuticals (NASDAQ:REGN), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The investment seeks to provide long-term capital appreciation. The fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of healthcare companies.

Market Cap

The average market capitalization across the JPMorgan Healthcare Leaders ETF (JDOC) ETF is 105.36B. The market cap for tickers in the group ranges from 25.7B to 1.06T. LLY holds the highest valuation in this group at 1.06T. The lowest valued company is INSM at 25.7B.

High and low price notable news

The average weekly price growth across all stocks in the JPMorgan Healthcare Leaders ETF (JDOC) ETF was 16%. For the same ETF, the average monthly price growth was 44%, and the average quarterly price growth was 276%. CVS experienced the highest price growth at 0%, while INSM experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the JPMorgan Healthcare Leaders ETF (JDOC) ETF was 6%. For the same stocks of the ETF, the average monthly volume growth was 27% and the average quarterly volume growth was 18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 50
Price Growth Rating: 49
SMR Rating: 63
Profit Risk Rating: 69
Seasonality Score: 16 (-100 ... +100)
View a ticker or compare two or three
JDOC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
J.P. Morgan Exchange-Traded Fund Trust390 Madison AvenueNew York
Phone
(844) 457-6383
Web
jpmorganfunds.com
JDOC in downward trend: price dove below 50-day moving average on September 08, 2026